Cancer patients receiving a certain type of immunotherapy were twice as likely to be alive after three years if they received ...
The probability of developing ocular EIMs was comparable across treatment classes among patients with HLA-B27-associated diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback